| Dynamics of cervical langerhans cell counts in the course of HPV-positive CIN treatment with the use of human recombinant interferon gamma. | |
| | |
MedLine Citation:
|
PMID: 15991530 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Langerhans cells play a pivotal role as professional antigens presenting cells in cervical epithelium, thus changes in their density or/and function may profoundly influence the proper activation of the afferent arm of immune response in cases of HPV-related intraepithelial lesions. AIM OF THE STUDY: Assessment of intraepithelial Langerhans cell count changes in CIN I/CIN II after human recombinant interferon gamma (IFNgamma) application and correlation with clinical outcome. MATERIAL & METHODS: The present study is a part of prospective trial on IFNgamma application in the treatment of CIN I/CINII associated with high-risk HPV infection. Seventeen subjects underwent uniform IFNgamma treatment (four intracervical injections in a two-day interval for a total dose of 6,000,000 IU). Langerhans cells were stained within cervical punch biopsy specimens with the use of polyclonal anti-S-100 antibody according to the three-step indirect peroxidase protocol, and their mean count calculated for the following groups: before IFNgamma treatment launching, immediately after completion of the treatment, and after two months of follow-up. RESULTS: The analysis revealed a rapid and significant increase in Lagerhans' cell count immediately after treatment completion (21.17/mm2 and 25.94/mm2, respectively, at p = 0.019) which further increased in the group of complete response (in 9 subjects; 32.22/mm2). After transient elevation of the Langerhans' cell count it returned to a level even lower than initially in the non-responder group (4 subjects; 20.25/mm2). CONCLUSION: Our data strongly support the observation from static studies suggesting that regression of HPV-related cervical lesions is associated with increased density of epithelial Langerhans cells. |
| | |
Authors:
|
M Sikorski; T Bieda; M Bobek; H Zrubek |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of gynaecological oncology Volume: 26 ISSN: 0392-2936 ISO Abbreviation: Eur. J. Gynaecol. Oncol. Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-07-04 Completed Date: 2005-10-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8100357 Medline TA: Eur J Gynaecol Oncol Country: Italy |
Other Details:
|
Languages: eng Pagination: 294-8 Citation Subset: IM |
Affiliation:
|
Genix-Medical Centre, Lublin, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / administration & dosage* Antiviral Agents / administration & dosage Cell Count Cervical Intraepithelial Neoplasia / drug therapy*, immunology Cervix Uteri / drug effects, immunology Female Humans Injections, Intralesional Interferon-gamma, Recombinant / administration & dosage* Langerhans Cells / drug effects, immunology* Middle Aged Papillomaviridae Papillomavirus Infections / drug therapy, immunology Remission Induction Treatment Outcome Uterine Cervical Neoplasms / drug therapy*, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Antiviral Agents; 0/Interferon-gamma, Recombinant |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The significance of Doppler flow in early detection of uterine sarcoma in older primigravida pregnan...
Next Document: A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary pe...